Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery - Full Text View

Home Search Study Topics Glossary

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery

This study has been completed.

Sponsored by:	Sirion Therapeutics, Inc.
Information provided by:	Sirion Therapeutics, Inc.
ClinicalTrials.gov Identifier:	NCT00429923

Purpose

The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.

Condition	Intervention	Phase
Inflammation	Drug: Difluprednate	Phase III

Drug Information available for: Difluprednate

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Eligibility

Ages Eligible for Study:	2 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

Systemic administration of any corticosteroid in the 2 weeks prior to study enrollment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00429923

Locations

United States, Missouri
Comprehensive Eye Care
Washington, Missouri, United States, 63090

Sponsors and Collaborators

Sirion Therapeutics, Inc.

Investigators

Study Chair:

Roger Vogel

Sirion Therapeutics, Inc.

More Information

Study ID Numbers:	ST-601A-002a
Study First Received:	January 31, 2007
Last Updated:	October 22, 2007
ClinicalTrials.gov Identifier:	NCT00429923
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Inflammation

Additional relevant MeSH terms:

Pathologic Processes

ClinicalTrials.gov processed this record on January 16, 2009